Comparison of AVEO Pharmaceuticals Inc. (AVEO) and ChemoCentryx Inc. (NASDAQ:CCXI)

Both AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) and ChemoCentryx Inc. (NASDAQ:CCXI) are each other’s competitor in the Biotechnology industry. Thus the contrast of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AVEO Pharmaceuticals Inc. 4.01M 18.45 23.65M -0.20 0.00
ChemoCentryx Inc. 89.84M 5.96 12.47M 0.19 57.10

Table 1 demonstrates AVEO Pharmaceuticals Inc. and ChemoCentryx Inc.’s top-line revenue, earnings per share (EPS) and valuation.


Table 2 shows AVEO Pharmaceuticals Inc. and ChemoCentryx Inc.’s return on assets, return on equity and net margins.

Net Margins Return on Equity Return on Assets
AVEO Pharmaceuticals Inc. -589.78% 48.1% -69.9%
ChemoCentryx Inc. 13.88% 32.2% 6.5%

Volatility & Risk

AVEO Pharmaceuticals Inc. is 13.00% more volatile than S&P 500 because the company has a beta of 1.13. Competitively, ChemoCentryx Inc. is 26.00% more volatile than S&P 500, because of the 1.26 beta.


AVEO Pharmaceuticals Inc.’s Current Ratio is 1.1 while its Quick Ratio is 1.1. On the competitive side is, ChemoCentryx Inc. which has a 2.9 Current Ratio and a 2.9 Quick Ratio. ChemoCentryx Inc. is better positioned to pay off short and long-term obligations compared to AVEO Pharmaceuticals Inc.

Analyst Ratings

The table given features the ratings and recommendations for AVEO Pharmaceuticals Inc. and ChemoCentryx Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
AVEO Pharmaceuticals Inc. 0 2 2 2.50
ChemoCentryx Inc. 0 0 4 3.00

AVEO Pharmaceuticals Inc. has a consensus price target of $2, and a 238.93% upside potential. Meanwhile, ChemoCentryx Inc.’s average price target is $21, while its potential upside is 106.08%. The results from earlier shows that analysts view suggest that AVEO Pharmaceuticals Inc. seems more appealing than ChemoCentryx Inc.

Institutional & Insider Ownership

Roughly 41.9% of AVEO Pharmaceuticals Inc. shares are owned by institutional investors while 55.5% of ChemoCentryx Inc. are owned by institutional investors. About 0.3% of AVEO Pharmaceuticals Inc.’s share are owned by insiders. Competitively, ChemoCentryx Inc. has 4.7% of it’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
AVEO Pharmaceuticals Inc. -15.19% -19.85% -72.92% -80.67% -80.4% -64.96%
ChemoCentryx Inc. 1.1% -9.97% 6.99% -13.64% 12.22% 1.01%

For the past year AVEO Pharmaceuticals Inc. has -64.96% weaker performance while ChemoCentryx Inc. has 1.01% stronger performance.


On 10 of the 13 factors ChemoCentryx Inc. beats AVEO Pharmaceuticals Inc.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The companyÂ’s pipeline of product candidates include Tivozanib, a vascular endothelial growth factor (VEGF) to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. Its development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension. The company has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. VincentÂ’s Hospital Sydney Limited; Biogen Idec International GmbH; and Kyowa Hakko Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan (CCX168), an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). The company also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis. It has a partnership with Vifor (International) Ltd. for the geographic commercial rights of Avacopan in Europe and other international markets. ChemoCentryx, Inc. was founded in 1997 and is headquartered in Mountain View, California.